A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease.
about
Characterization of dextran sodium sulfate-induced inflammation and colonic tumorigenesis in Smad3(-/-) mice with dysregulated TGFβAntidepressants and inflammatory bowel disease: a systematic reviewPattern Recognition Receptors in Cancer Progression and MetastasisThe Yin and Yang of Toll-like receptors in cancerAssociation among genetic predisposition, gut microbiota, and host immune response in the etiopathogenesis of inflammatory bowel diseaseDiscovery and validation of a new class of small molecule Toll-like receptor 4 (TLR4) inhibitorsThe roles of bacteria and TLR4 in rat and murine models of necrotizing enterocolitisShift towards pro-inflammatory intestinal bacteria aggravates acute murine colitis via Toll-like receptors 2 and 4.Toll-like receptor 4 decoy, TOY, attenuates gram-negative bacterial sepsis.The induction of colitis and ileitis in mice is associated with marked increases in intestinal concentrations of stimulants of TLRs 2, 4, and 5Role of gut microbiota in a zebrafish model with chemically induced enterocolitis involving toll-like receptor signaling pathways.Toll-like receptor 4 and hepatic fibrogenesisTRIF modulates TLR5-dependent responses by inducing proteolytic degradation of TLR5Toll-like receptors in the pathogenesis of alcoholic liver disease.Toll-like receptors in inflammatory bowel diseases: a decade later.Novel genetic markers in inflammatory bowel disease.Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis.Loss of TLR2 worsens spontaneous colitis in MDR1A deficiency through commensally induced pyroptosis.DNA attenuates enterocyte Toll-like receptor 4-mediated intestinal mucosal injury after remote trauma.TLR2 mediates gap junctional intercellular communication through connexin-43 in intestinal epithelial barrier injuryThe gut microbiome, kidney disease, and targeted interventions.Worms, flies and four-legged friends: the applicability of biological models to the understanding of intestinal inflammatory diseases.Lactobacillus amylovorus inhibits the TLR4 inflammatory signaling triggered by enterotoxigenic Escherichia coli via modulation of the negative regulators and involvement of TLR2 in intestinal Caco-2 cells and pig explantsModulating LPS signal transduction at the LPS receptor complex with synthetic Lipid A analoguesNon-viral delivery of nuclear factor-kappaB decoy ameliorates murine inflammatory bowel disease and restores tissue homeostasis.Toll-like receptors in liver fibrosis: cellular crosstalk and mechanismsGlial-cell-derived neuroregulators control type 3 innate lymphoid cells and gut defence.Elevated lipopolysaccharide in the colon evokes intestinal inflammation, aggravated in immune modulator-impaired mice.Novel susceptibility genes in inflammatory bowel disease.No longer an innocent bystander: epithelial toll-like receptor signaling in the development of mucosal inflammationBench-to-bedside review: sepsis, severe sepsis and septic shock - does the nature of the infecting organism matter?Molecular pathogenesis of inflammatory bowel disease: genotypes, phenotypes and personalized medicine.How important are Toll-like receptors for antimicrobial responses?TLR4-induced IFN-gamma production increases TLR2 sensitivity and drives Gram-negative sepsis in mice.Opposing functions of IKKbeta during acute and chronic intestinal inflammation.Regulation of interactions of Gram-negative bacterial endotoxins with mammalian cells.TLR2 in murine atherosclerosis.Severe sepsis and Toll-like receptors.The role of TLR activation in inflammation.Protective effect of naringenin against experimental colitis via suppression of Toll-like receptor 4/NF-κB signalling
P2860
Q21559539-DDFC183F-B094-46DE-BAB2-FA434859E11EQ24676951-CC619F44-7E51-47B9-BE81-1C77D4030E80Q26798034-64A8CBA6-379E-446D-AF39-350A4D253E23Q26851526-92D71BF5-DBA0-460E-B51C-08EDB25CAA2DQ27006589-D74A4CF7-8D8C-4F85-9604-F20E90096A87Q28533856-6AF40DAC-80A7-4B94-BE51-FA65A0E9410EQ33254555-DB6C63A5-C7EB-422A-B43F-397B80E7D6DDQ33291759-11EFEB98-B4BD-4988-8A0F-B712D77193EDQ33509524-298E77BC-40AC-46DA-9695-199E156F1E5EQ33531757-1DDFA6EB-CD83-433B-93A4-9AC3F5BD3DD6Q33731168-0E714D0F-8105-4A27-8B09-64BA301E4D7DQ33905721-8DEDF0C2-B8D1-480A-B41B-DC1E03DE883CQ33967283-5041C4D5-2874-4936-824C-A5D94E5A3285Q34106192-1545372C-B634-44FB-AF46-ABEC3C66473EQ34134813-E6B32AE6-FC5F-43E4-86DA-CE850F49D67EQ34233119-39FA10D5-50BE-43F3-964A-780C9EDD2B67Q34321742-7A94F058-F5C1-4D3F-8B7D-5AA439EC3128Q34342336-187C13DE-DA2C-4EA3-8208-1810827CB17AQ34979970-218C238B-C78C-48EC-BAEE-641615B027CDQ34986938-6DD2E38E-1A82-468F-8BA7-B08EB55CCA93Q35042986-98619A2B-08A0-40F0-BB3A-937742C988A3Q35070715-E552D961-CAA3-42A0-995E-AAFF66AAEF49Q35148077-F623968F-656D-43EE-8A39-09B456C844F2Q35737359-FD338EB1-A503-404E-B9C3-01C019C884A9Q35761406-F6568233-7690-4944-BFA1-628487409533Q35977675-A48E359B-FA47-4E77-97BF-57243308B354Q36074979-717EF26E-A63A-4F20-9497-C7A4126FB6A8Q36176048-5CA27252-6F28-4F54-ABB0-35324B291274Q36446297-66C3E590-D2EA-4F41-86D7-6A4331E71550Q36732312-40773296-7473-4068-8520-C04F5C02D03EQ36787173-F80465B4-F29F-4D2D-BC81-3ACE4C94E99EQ36801108-4D21DBAD-E911-424D-9029-80D95D738F03Q36830211-CCB1784E-9351-48E5-9846-ACC1F0972E41Q36851875-53F12706-1391-44EF-BB80-618ACB6CD9B6Q36937167-087A01CB-B2BB-4390-9FA8-42506FF5E00FQ36961095-927AE8EC-5747-4EE4-BAD9-11033283FE41Q37023850-A18BDBDA-BB21-48DF-B196-19E4DB6BB061Q37028885-C0636C15-7415-432B-BC78-08C0DC1DEDF4Q37045751-8719D4E7-34E1-4B41-B652-4BDC5E104672Q37053805-B167F6D6-1615-48DA-B4EC-911A10A2373A
P2860
A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
A synthetic TLR4 antagonist ha ...... of inflammatory bowel disease.
@en
A synthetic TLR4 antagonist ha ...... of inflammatory bowel disease.
@nl
type
label
A synthetic TLR4 antagonist ha ...... of inflammatory bowel disease.
@en
A synthetic TLR4 antagonist ha ...... of inflammatory bowel disease.
@nl
prefLabel
A synthetic TLR4 antagonist ha ...... of inflammatory bowel disease.
@en
A synthetic TLR4 antagonist ha ...... of inflammatory bowel disease.
@nl
P2093
P921
P1476
A synthetic TLR4 antagonist ha ...... of inflammatory bowel disease.
@en
P2093
Afsaneh Mozaffarian
Axel G Stöver
David A Johnson
David H Persing
Eric Jeffery
Helle Bielefeldt-Ohmann
Jean da Silva Correia
Madeline M Fort
Peter Probst
R Thomas Crane
P304
P356
10.4049/JIMMUNOL.174.10.6416
P407
P577
2005-05-01T00:00:00Z